Arsenal Biosciences has closed an oversubscribed $325 million Series C financing round to support its development of CAR T-cell therapies for solid tumours. The funding round included new investors ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (NVIDIA’s venture capital arm), Luma Group, funds and accounts advised by T Rowe Price Associates, Rock […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!